CAR-T therapy

R&D

Purity, potency, and safety – affordably – in stem cell ther...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of s

News

JPM: Precision Bio continues offload of CAR-T rights

Precision BioSciences has agreed to a second licensing deal for its ‘off-the-shelf’ CAR-T therapy azer-cel, as it switches focus to developing in vivo applications of its

News

Leschly steps down as 2seventy wields the axe

2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also

Oncology

War in the Blood: The battle takes shape in the burgeoning E...

With the continuing evolution of the CAR-T landscape, Research Partnership speaks to payers across Europe to investigate the market access and commercialisation potential for manufacturers

R&D

Oncology R&D hits new heights, but that creates problems

The number of people globally who are being treated for cancer is steadily going up each year.

Oncology

ASCO 2023 – Martin Vogel and Edmond Chan

In another look back to ASCO 2023, pharmaphorum editor-in-chief Jonah Comstock spoke with Janssen's Martin Vogel and Edmond Chan, EMEA leads for oncology and haematology, respectively.